Rapid development of an efficacious vaccine against the viral pathogen severe acute
respiratory syndrome coronavirus-2 (SARS-CoV-2), the cause of the coronavirus disease …

Background The rapid process of research and development and lack of follow-up time post-
vaccination aroused great public concern about the safety profile of COVID-19 vaccine …

In response to the SARS‑CoV‑2 outbreak, and the resulting COVID‑19 pandemic, a global
competition to develop an anti‑COVID‑19 vaccine has ensued. The targeted time frame for …

Covid-19 Vaccines — Immunity, Variants, Boosters | NEJM Skip to main content NEJM Group
Follow Us Facebook Twitter Instagram YouTube LinkedIn Prepare to become a physician …

The entire world has been suffering from the coronavirus disease 2019 (COVID‐19)
pandemic since March 11, 2020. More than a year later, the COVID‐19 vaccination brought …

Phase 3 randomized-controlled trials have provided promising results of COVID-19 vaccine
efficacy, ranging from 50 to 95% against symptomatic disease as the primary endpoints …

With a death toll of over one million worldwide, the COVID-19 pandemic caused by SARS-
CoV-2 has become the most devastating humanitarian catastrophe in recent decades. The …

Vaccines are needed to protect from SARS-CoV-2, the virus causing COVID-19. Vaccines
that induce large quantities of high affinity virus-neutralizing antibodies may optimally …

Introduction Several vaccine candidates have been developed using different platforms,
including nucleic acids (DNA and RNA), viral vectors (replicating and non-replicating), virus …

Abstract Coronavirus Disease 2019 (COVID-19) has been the most severe public health
challenge in this century. Two years after its emergence, the rapid development and …